Matthew Ellis

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Predicting endocrine therapy responsiveness in breast cancer
    Cynthia X Ma
    Section of Medical Oncology, Division of Oncology, Department of Internal Medicine, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Oncology (Williston Park) 23:133-42. 2009
  2. ncbi request reprint Mutational analysis of breast cancer: guiding personalized treatments
    Matthew J Ellis
    Division of Medical Oncology, Section of Breast Oncology, Washington University School of Medicine, Siteman Cancer Center, 660 South Euclid Ave, CB 8069, St Louis, MO 63110, USA Electronic address
    Breast 22:S19-21. 2013
  3. pmc PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
    Roy R L Bastien
    The ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
    BMC Med Genomics 5:44. 2012
  4. pmc The genomic landscape of breast cancer as a therapeutic roadmap
    Matthew J Ellis
    Division of Medical Oncology, Section of Breast Oncology, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Cancer Discov 3:27-34. 2013
  5. pmc Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study
    Matthew J Ellis
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    JAMA 302:774-80. 2009
  6. pmc Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
    Matthew J Ellis
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63119, USA
    Breast Cancer Res Treat 119:379-90. 2010
  7. pmc Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
    Matthew J Ellis
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63119, USA
    Breast Cancer Res Treat 116:371-8. 2009
  8. pmc Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
    Cesar G Sanchez
    Department of Hematology Oncology, School of Medicine, Pontificia Universidad Catolica de Chile, Lira 85, 4th Floor, Santiago 8330023, Chile
    Breast Cancer Res 13:R21. 2011
  9. pmc Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
    Matthew J Ellis
    Siteman Cancer Center, Washington University in St Louis, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Clin Oncol 29:2342-9. 2011
  10. pmc Femara and the future: tailoring treatment and combination therapies with Femara
    Matthew Ellis
    Medical Oncology, Washington University, 660 Euclid Ave, Campus Box 8056, St Louis, MO 63110, USA
    Breast Cancer Res Treat 105:105-15. 2007

Research Grants

  1. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2003
  2. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2004
  3. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2005
  4. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2006
  5. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2007
  6. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2009
  7. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew J Ellis; Fiscal Year: 2010

Collaborators

Detail Information

Publications35

  1. ncbi request reprint Predicting endocrine therapy responsiveness in breast cancer
    Cynthia X Ma
    Section of Medical Oncology, Division of Oncology, Department of Internal Medicine, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Oncology (Williston Park) 23:133-42. 2009
    ..This article reviews ongoing progress in the effort to identify predictors of endocrine therapy responsiveness for breast cancer and discusses the value of "pre-treatment" vs "on-treatment" tumor profiling for predicting outcomes...
  2. ncbi request reprint Mutational analysis of breast cancer: guiding personalized treatments
    Matthew J Ellis
    Division of Medical Oncology, Section of Breast Oncology, Washington University School of Medicine, Siteman Cancer Center, 660 South Euclid Ave, CB 8069, St Louis, MO 63110, USA Electronic address
    Breast 22:S19-21. 2013
    ..This article reviews conclusions from recent breast cancer 'omics profiling' papers and considers pathways forward for extracting medically valuable information from large dimension data sets...
  3. pmc PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
    Roy R L Bastien
    The ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA
    BMC Med Genomics 5:44. 2012
    ..Discrepancies between these methods may lead to different treatment decisions...
  4. pmc The genomic landscape of breast cancer as a therapeutic roadmap
    Matthew J Ellis
    Division of Medical Oncology, Section of Breast Oncology, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Cancer Discov 3:27-34. 2013
    ..In this Prospective, we summarize some of the headline conclusions from 6 recent breast cancer "omics profiling" articles in Nature, with an emphasis on the implications for systemic therapy...
  5. pmc Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study
    Matthew J Ellis
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    JAMA 302:774-80. 2009
    ..Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells to low-dose estradiol therapy...
  6. pmc Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
    Matthew J Ellis
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63119, USA
    Breast Cancer Res Treat 119:379-90. 2010
    ..Nonetheless, as with other recent studies, a favorable interaction between PIK3CA KD mutation and prognosis was detected. The mechanism for the favorable prognostic impact of PIK3CA mutation status therefore remains unexplained...
  7. pmc Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
    Matthew J Ellis
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63119, USA
    Breast Cancer Res Treat 116:371-8. 2009
    ..Expression of aromatase by malignant breast epithelial cells and/or the surrounding stroma implies local estrogen production that could influence the outcome of endocrine therapy for breast cancer...
  8. pmc Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
    Cesar G Sanchez
    Department of Hematology Oncology, School of Medicine, Pontificia Universidad Catolica de Chile, Lira 85, 4th Floor, Santiago 8330023, Chile
    Breast Cancer Res 13:R21. 2011
    ....
  9. pmc Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
    Matthew J Ellis
    Siteman Cancer Center, Washington University in St Louis, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Clin Oncol 29:2342-9. 2011
    ..To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations...
  10. pmc Femara and the future: tailoring treatment and combination therapies with Femara
    Matthew Ellis
    Medical Oncology, Washington University, 660 Euclid Ave, Campus Box 8056, St Louis, MO 63110, USA
    Breast Cancer Res Treat 105:105-15. 2007
    ..Microarray gene profiling studies, designed to detect letrozole-responsive targets, are currently under way to understand how the use of the drug can be tailored more efficiently to specific patient needs...
  11. pmc PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer
    Farrokh Dehdashti
    Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology, St Louis, MO 63110, USA
    Breast Cancer Res Treat 113:509-17. 2009
    ....
  12. ncbi request reprint Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials
    Yu Tao
    Siteman Cancer Center and Washington University in St Louis, Campus Box 8506, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Steroid Biochem Mol Biol 95:91-5. 2005
    ....
  13. doi request reprint Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer
    Nicola Napoli
    Washington University School of Medicine, St Louis, MO, USA
    Bone 55:309-14. 2013
    ..The objective of this study is to determine the influence of polymorphisms in the CYP19A1 gene on bone loss among patients taking aromatase inhibitors for ER+ breast cancer...
  14. ncbi request reprint Overcoming endocrine therapy resistance by signal transduction inhibition
    Matthew Ellis
    Siteman Cancer Center, Washington University, St Louis, Missouri 63110, USA
    Oncologist 9:20-6. 2004
    ..With a number of phase III clinical trials now under way, major advances in the endocrine treatment of advanced disease are possible...
  15. pmc PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer
    Robert J Crowder
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Cancer Res 69:3955-62. 2009
    ..Our results suggest that PI3K inhibitors should target both p110alpha and p110beta catalytic subunits, whether wild-type or mutant, and be combined with endocrine therapy for maximal efficacy when treating ER(+) breast cancer...
  16. ncbi request reprint The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers
    P Kelly Marcom
    Siteman Comprehensive Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8056, St Louis, MO, USA
    Breast Cancer Res Treat 102:43-9. 2007
    ..The efficacy of the aromatase inhibitor letrozole in combination with trastuzumab was therefore tested in a Phase 2 study...
  17. pmc Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study
    Mike G Martin
    Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8007, Saint Louis, MO 63110, USA
    Breast Cancer Res Treat 118:593-8. 2009
    ..This association maybe explained by either greater chemotherapy exposure or an interaction between therapy and genetic predisposition...
  18. pmc A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer
    Ying Liu
    Division of Health Behavior Research, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63108, USA
    Breast Cancer Res Treat 124:835-44. 2010
    ..Educating early-stage breast cancer patients about their actual risk could result in more realistic recurrence-risk perceptions, and increasing social support could help alleviate anxiety associated with exaggerated risk perceptions...
  19. pmc Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
    Matthew J Ellis
    Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63119, USA
    J Natl Cancer Inst 100:1380-8. 2008
    ....
  20. ncbi request reprint Neoadjuvant endocrine therapy as a drug development strategy
    Matthew J Ellis
    Washington University School of Medicine, St Louis, Missouri, USA
    Clin Cancer Res 10:391S-5S. 2004
    ..However, the optimal clinical investigative approaches, analytical techniques, and appropriate surrogate end points have yet to be identified and are the subject of several ongoing or planned clinical studies...
  21. ncbi request reprint Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy
    Matthew J Ellis
    Washington University School of Medicine, Section of Medical Oncology and Breast Cancer Program, St Louis, Missouri, USA
    Ann Surg Oncol 11:9S-17S. 2004
    ..Ongoing investigations are examining gene expression profile changes associated with neoadjuvant endocrine therapy, as well as inhibitors of growth factor signaling that may modulate tamoxifen resistance...
  22. ncbi request reprint Successful targeting of ErbB2 receptors-is PTEN the key?
    Robert J Crowder
    Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, Campus Box 8056, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Cancer Cell 6:103-4. 2004
    ..Resistance to trastuzumab occurs when PTEN function is lost, suggesting that PTEN activation is a critical component of the therapeutic effect...
  23. pmc Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway
    Robert J Crowder
    Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, St Louis, Missouri, USA
    Breast Cancer Res 7:212-4. 2005
    ....
  24. ncbi request reprint Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
    Matthew J Ellis
    Siteman Comprehensive Cancer Center, Washington University School of Medicine, Campus Box 8056, 660 S Euclid Ave, St Louis, MO 63110, USA
    J Clin Oncol 24:3019-25. 2006
    ....
  25. ncbi request reprint Neoadjuvant endocrine therapy for locally advanced breast cancer
    Cynthia X Ma
    Department of Oncology, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Semin Oncol 33:650-6. 2006
    ..In this review, we outline the rationale for preoperative endocrine therapy, and consider predictive models for endocrine therapy responsiveness in this setting...
  26. ncbi request reprint Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status
    Matthew J Ellis
    Duke University Comprehensive Cancer Center, Campus Box 8056, 660 South Euclid, Durham, NC 27710, USA
    Cancer Res 63:6523-31. 2003
    ....
  27. ncbi request reprint Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data
    Matthew J Ellis
    Siteman Comprehensive Cancer Center and Washington University School of Medicine, St Louis, MO 63110, USA
    Curr Med Res Opin 22:2479-87. 2006
    ..This review will compare the current available efficacy, safety, and cost-effectiveness data for AIs in the initial adjuvant and switch adjuvant settings...
  28. pmc Letrozole in the neoadjuvant setting: the P024 trial
    Matthew J Ellis
    Medical Oncology, Washington University, Campus Box 8056, 660 Euclid Ave, St Louis, MO 63110, USA
    Breast Cancer Res Treat 105:33-43. 2007
    ..0009). Thus, neoadjuvant letrozole is safe and superior to tamoxifen in the treatment of postmenopausal women with HR+ locally advanced breast cancer...
  29. ncbi request reprint A luminal breast cancer genome atlas: progress and barriers
    Matthew J Ellis
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63119, USA
    J Steroid Biochem Mol Biol 106:125-9. 2007
    ....
  30. pmc Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial
    Rebecca Aft
    Department of Surgery, Washington University School of Medicine, St Louis, MO 63110, USA
    Lancet Oncol 11:421-8. 2010
    ..The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells (DTCs) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer...
  31. doi request reprint Neoadjuvant endocrine therapy for breast cancer
    Jane S Chawla
    Division of Oncology, Department of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Surg Oncol Clin N Am 19:627-38. 2010
    ....
  32. pmc High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer
    Nicola Napoli
    Division of Bone and Mineral Diseases at Washington University School of Medicine, St Louis, Missouri, USA
    Breast J 16:609-16. 2010
    ..Future studies may be needed to establish the contribution of low vitamin D, if any, on the prevalence of musculoskeletal pains in women on AIs...
  33. pmc "I'm pregnant and I have breast cancer"
    Michael J Naughton
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    BMC Cancer 7:93. 2007
    ..There is general consensus that both surgery and chemotherapy are relatively safe after the first trimester of pregnancy. It is generally agreed that therapeutic radiation, if necessary, should be delayed until completion of pregnancy...
  34. pmc Genome remodelling in a basal-like breast cancer metastasis and xenograft
    Li Ding
    The Genome Center at Washington University, St Louis, Missouri 63108, USA
    Nature 464:999-1005. 2010
    ..The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour...
  35. doi request reprint Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies
    Paula M Fracasso
    Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
    Cancer Chemother Pharmacol 63:451-8. 2009
    ..To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of weekly docosahexaenoic acid-paclitaxel (DHA-paclitaxel), a taxane fatty acid conjugate...

Research Grants7

  1. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2003
    ..abstract_text> ..
  2. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2004
    ..abstract_text> ..
  3. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2005
    ..abstract_text> ..
  4. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2006
    ..abstract_text> ..
  5. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2007
    ..abstract_text> ..
  6. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew Ellis; Fiscal Year: 2009
    ....
  7. Novel Biomarkers for Aromatase Inhibitor Therapy
    Matthew J Ellis; Fiscal Year: 2010
    ....